gossypol and ponatinib

gossypol has been researched along with ponatinib in 2 studies

Research

Studies (2)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	0 (0.00)	29.6817
2010's	1 (50.00)	24.3611
2020's	1 (50.00)	2.80

Authors

Authors	Studies
Davis, MI; Khan, J; Li, SQ; Patel, PR; Shen, M; Sun, H; Thomas, CJ	1
El-Lakkany, NM; Elkattan, HH; Elsisi, AE	1

Other Studies

2 other study(ies) available for gossypol and ponatinib

Article	Year
Identification of potent Yes1 kinase inhibitors using a library screening approach. Bioorganic & medicinal chemistry letters, 2013, Aug-01, Volume: 23, Issue:15 Topics: Binding Sites; Cell Line; Cell Survival; Drug Design; Humans; Hydrogen Bonding; Molecular Docking Simulation; Protein Kinase Inhibitors; Protein Structure, Tertiary; Proto-Oncogene Proteins c-yes; Small Molecule Libraries; Structure-Activity Relationship	2013
The ponatinib/gossypol novel combination provides enhanced anticancer activity against murine solid Ehrlich carcinoma via triggering apoptosis and inhibiting proliferation/angiogenesis. Toxicology and applied pharmacology, 2021, 12-01, Volume: 432 Topics: Angiogenesis Inhibitors; Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Apoptosis Regulatory Proteins; Carcinoma, Ehrlich Tumor; Cell Line, Tumor; Cell Proliferation; Female; Gossypol; Imidazoles; Mice; Neovascularization, Pathologic; Oxidative Stress; Pyridazines; Receptor, Fibroblast Growth Factor, Type 4; Signal Transduction; Tumor Burden; Vascular Endothelial Growth Factor A	2021

Article

Year

Identification of potent Yes1 kinase inhibitors using a library screening approach.

Bioorganic & medicinal chemistry letters, 2013, Aug-01, Volume: 23, Issue:15

Topics: Binding Sites; Cell Line; Cell Survival; Drug Design; Humans; Hydrogen Bonding; Molecular Docking Simulation; Protein Kinase Inhibitors; Protein Structure, Tertiary; Proto-Oncogene Proteins c-yes; Small Molecule Libraries; Structure-Activity Relationship

2013

The ponatinib/gossypol novel combination provides enhanced anticancer activity against murine solid Ehrlich carcinoma via triggering apoptosis and inhibiting proliferation/angiogenesis.

Toxicology and applied pharmacology, 2021, 12-01, Volume: 432

Topics: Angiogenesis Inhibitors; Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Apoptosis Regulatory Proteins; Carcinoma, Ehrlich Tumor; Cell Line, Tumor; Cell Proliferation; Female; Gossypol; Imidazoles; Mice; Neovascularization, Pathologic; Oxidative Stress; Pyridazines; Receptor, Fibroblast Growth Factor, Type 4; Signal Transduction; Tumor Burden; Vascular Endothelial Growth Factor A

2021